Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Hartwig W, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013; 14:476-85; PMID:24079875; http://dx.doi.org/10.1016/S1470-2045(13)70172-4
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011 Dec 1;29(34):4548-54; PMID:21969517; http://dx.doi.org/10.1200/JCO.2011.36.5742
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al; Groupe Tumours Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817-25; PMID:21561347; http://dx.doi.org/10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, et al. Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. J Clin Oncol 2014 Jun 30; 32(23):2423-9. pii: JCO.2013.53.6995.
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012; 22:33-40; PMID:22210179; http://dx.doi.org/10.1016/j.semcancer.2011.12.005
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005
   PubMed Web of Science ®Google Scholar
• Johnston FM, Tan MC, Tan BR Jr, Porembka MR, Brunt EM, Linehan DC, Simon PO JR, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009; 15:6511-18; PMID:19843662
   PubMed Web of Science ®Google Scholar
• Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K, et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006; 12:1365-1372; PMID:16489095
   PubMed Web of Science ®Google Scholar
• Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, et al. Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 2004; 95:583-87; PMID:15245594
   PubMed Web of Science ®Google Scholar
• Ueda M, Miura Y, Kunihiro O, Ishikawa T, Ichikawa Y, Endo I, Sekido H, Togo S, Shimada H. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepato-Gastroenterology 2005; 52:398-403; PMID:15816444
   PubMed Web of Science ®Google Scholar
• Seki K, Suda T, Aoyagi Y, Sugawara S, Natsui M, Motoyama H, Shirai Y, Sekine T, Kawai H, Mita Y, et al. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptasemessenger RNA in pancreatic juice with sample qualification. Clin Cancer Res 2001; 7:1976-81; PMID:11448913
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Søreide O, Thorsby E, Gaudernack G. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995; 346:1399-1400, 1995; PMID:7475823
   PubMed Web of Science ®Google Scholar
• Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen surviving. Cancer Immunol Immunother 2006; 55:1294-1298; PMID:16315030
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991; 47:148-54; PMID:2072697
   PubMed Web of Science ®Google Scholar
• Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 2009; 100:1243-1247; PMID:19432892
   PubMed Web of Science ®Google Scholar
• Maacke H, Kessler A, Schmiegel W, Roeder C, Vogel I, Deppert W, Kalthoff H. Overexpression of p53 protein during pancreatitis. Br J Cancer 1997; 75:1501-04; PMID:9166944
   PubMed Web of Science ®Google Scholar
• Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer 2009; 125:639-48; PMID:19425054
   PubMed Web of Science ®Google Scholar
• Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103:97-100; PMID:12455059
   PubMed Web of Science ®Google Scholar
• Tewari N, Zaitoun AM, Arora A, Madhusudan S, Ilyas M, Lobo DN. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC Cancer 2013; 13:436; PMID:24063854
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59:1593-600; http://dx.doi.org/10.1007/s00262-010-0855-8; PMID:20414655
   PubMed Web of Science ®Google Scholar
• Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60:1419-30; PMID:21644036.; http://dx.doi.org/10.1007/s00262-011-1028-0
   PubMed Web of Science ®Google Scholar
• Zhao F, Obermann S, von Wasielewski R, Haile L, Manns MP, Korangy F, Greten TF. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009; 128:141-9; PMID:19689743; http://dx.doi.org/10.1111/j.1365-2567.2009.03105.x
   PubMed Web of Science ®Google Scholar
• Schmieder A, Michel J, Schönhaar K, Goerdt S, Schledzewski K. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol 2012; 22:289-97; PMID:22349514; http://dx.doi.org/10.1016/j.semcancer.2012.02.002
   PubMed Web of Science ®Google Scholar
• Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA, Sarukhan A. Mechanisms Driving Macrophage Diversity and Specialization in Distinct Tumor Microenvironments and Parallelisms with Other Tissues. Front Immunol 2014; 5:127; PMID:24723924
   PubMed Web of Science ®Google Scholar
• Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 2004; 57:630-6; PMID:15166270
   PubMed Web of Science ®Google Scholar
• Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011; 167:e211-9; PMID:19765725; http://dx.doi.org/10.1016/j.jss.2009.05.026
   PubMed Web of Science ®Google Scholar
• Nurieva R, Wang J, Sahoo A. T-cell tolerance in cancer. Immunotherapy 2013; 5:513-31; PMID:23638746; http://dx.doi.org/10.2217/imt.13.33
   PubMed Web of Science ®Google Scholar
• Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 2013; 34:33-40; PMID:22999714; http://dx.doi.org/10.1016/j.it.2012.08.005
   PubMed Web of Science ®Google Scholar
• Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, Fujii M, Maekawa Y, Yasutomo K, Shimada M. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006; 33:386-90; PMID:17079944
   PubMed Web of Science ®Google Scholar
• Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello P, et al. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 2013; 62:1249-60; PMID:23640603; http://dx.doi.org/10.1007/s00262-013-1429-3
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3 +regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34; PMID:17000676
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Hirooka S, Yamaki S, Yui R, Yamao J, Kim S, Kwon AH. Circulating CD4+CD25 +regulatory T cells in patients with pancreatic cancer. Pancreas 2012; 41:409-15; PMID:22158072; http://dx.doi.org/10.1097/MPA.0b013e3182373a66
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Yamao J, Kim S, Terakawa N, Takahashi K, Kwon AH. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J Surg Res 2012; 173:299-308; PMID:21195425; http://dx.doi.org/10.1016/j.jss.2010.09.027
   PubMed Web of Science ®Google Scholar
• Tjomsland V, Spångeus A, Sandström P, Borch K, Messmer D, Larsson M. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS One 2010; 5:e13441; PMID:20976171; http://dx.doi.org/10.1371/journal.pone.0013441
   PubMed Web of Science ®Google Scholar
• Pandha H, Rigg A, John J, Lemoine N. Loss of expression of antigen presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol 2007; 148:127-35; PMID:17302733
   PubMed Web of Science ®Google Scholar
• Aparicio-Pagés MN, Verspaget HW, Peña AS, Lamers CB. Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract. J Clin Lab Immunol 1991; 35:27-32; PMID:1668287
   PubMedGoogle Scholar
• Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011; 28:466-74; PMID:20354827; http://dx.doi.org/10.1007/s12032-010-9480-9
   PubMed Web of Science ®Google Scholar
• Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother 2012; 35:629-40; PMID:22996369
   PubMed Web of Science ®Google Scholar
• Schmitz-Winnenthal FH, Volk C, Z’graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Büchler MW, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005; 65:10079-87; PMID:16267034
   PubMed Web of Science ®Google Scholar
• Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004; 28:e26-31; PMID:14707745
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.20101876
   PubMed Web of Science ®Google Scholar
• Tassi E, Gavazzi F, Albarello L, Senyukov V, Longhi R, Dellabona P, Doglioni C, Braga M, Di Carlo V, Protti MP. Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 2008; 181:6595-603; PMID:19798410
   PubMed Web of Science ®Google Scholar
• Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007; 7:15-30; PMID:17305475
   PubMed Web of Science ®Google Scholar
• Geng L, Huang D, Liu J, Qian Y, Deng J, Li D, Hu Z, Zhang J, Jiang G, Zheng S. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 2008; 134:1021-7; PMID:18347814; http://dx.doi.org/10.1007/s00432-008-0364-8
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7; PMID:17404099
   PubMed Web of Science ®Google Scholar
• Shoji Y, Miyamoto M, Ishikawa K, Yoshioka T, Mishra R, Ichinokawa K, Matsumura Y, Itoh T, Shinohara T, Hirano S, et al. The CD40-CD154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma. J Surg Oncol 2011; 103:230-8; PMID:21337550; http://dx.doi.org/10.1002/jso.21812
   PubMed Web of Science ®Google Scholar
• Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009; 9:463; PMID:20035626; http://dx.doi.org/10.1186/1471-2407-9-463
   PubMed Web of Science ®Google Scholar
• Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009; 101:1709-16; PMID:19844235; http://dx.doi.org/10.1038/sj.bjc.6605375
   PubMed Web of Science ®Google Scholar
• Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007; 67:8344-50; PMID:17804750
   PubMed Web of Science ®Google Scholar
• Teraoka H, Sawada T, Yamashita Y, Nakata B, Ohira M, Ishikawa T, Nishino H, Hirakawa K. TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion. Int J Oncol 2001; 19:709-15; PMID:11562745
   PubMed Web of Science ®Google Scholar
• Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999; 155:537-47; PMID:10433946
   PubMed Web of Science ®Google Scholar
• Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006; 55:684-98; PMID:16094523
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006; 176:6752-61; PMID:16709834
   PubMed Web of Science ®Google Scholar
• Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 2008; 206:849-54; PMID:18471709; http://dx.doi.org/10.1016/j.jamcollsurg.2007.12.014
   PubMed Web of Science ®Google Scholar
• Söderlund J, Erhardt S, Kast RE. Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. J Neuroinflammation 2010; 7:44; PMID:20691089; http://dx.doi.org/10.1186/1742-2094-7-44
   PubMed Web of Science ®Google Scholar
• Cooper D, Ilarregui JM, Pesoa SA, Croci DO, Perretti M, Rabinovich GA. Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol 2010; 480:199-244; PMID:20816212; http://dx.doi.org/10.1016/S0076-6879(10)80011-4
   PubMed Web of Science ®Google Scholar
• Kuramitsu Y, Taba K, Ryozawa S, Yoshida K, Zhang X, Tanaka T, Maehara S, Maehara Y, Sakaida I, Nakamura K. Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 2010; 30:3367-72; PMID:20944110
   PubMed Web of Science ®Google Scholar
• Chung JC, Oh MJ, Choi SH, Bae CD. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J Surg 2008; 78:245-51; PMID:18366394; http://dx.doi.org/10.1111/j.1445-2197.2008.04429.x
   PubMed Web of Science ®Google Scholar
• Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M, Nishi N, Yamauchi A, Quintana FJ, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol 2010; 185:1383-92; PMID:20574007; http://dx.doi.org/10.4049/jimmunol.0903275
   PubMed Web of Science ®Google Scholar
• Peng W, Wang HY, Miyahara Y, Peng G, Wang RF. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 2008; 68:7228-36; PMID:18757439; http://dx.doi.org/10.1158/0008-5472.CAN-08-1245
   PubMed Web of Science ®Google Scholar
• Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, Lu CH, Li XY, Jiang F, Ni RZ. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol 2012; 138:1035-43; PMID:22367363; http://dx.doi.org/10.1007/s00432-012-1178-2
   PubMed Web of Science ®Google Scholar
• Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C, Bresalier RS. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signalling. PLoS One 2012; 7:e42699; PMID:22900040; http://dx.doi.org/10.1371/journal.pone.0042699
   PubMedGoogle Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-111; PMID:21283105.; http://dx.doi.org/10.1038/nrd3365
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, et al. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol, Biomarkers & Prevention 2008; 17:1520-1526; PMID:18559570; http://dx.doi.org/10.1158/1055-9965.EPI-08-0039
   PubMed Web of Science ®Google Scholar
• Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005; 11:3814-3820; PMID:15897581; http://dx.doi.org/10.1158/1078-0432.CCR-04-2304
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelinexpressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144-5149; PMID:17785569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0869
   PubMed Web of Science ®Google Scholar
• Filpula D, Zhao H. Releasable PEGylation of proteins with customized linkers. Adv Drug Delivery Rev 2008; 60:29-49; PMID:17884239; http://dx.doi.org/10.1016/j.addr.2007.02.001
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion antimesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15:5274-5279; PMID:19671873; http://dx.doi.org/10.1158/1078-0432.CCR-09-0062
   PubMed Web of Science ®Google Scholar
• Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010 Dec 15;16(24):6132-8; PMID:21037025; http://dx.doi.org/10.1158/1078-0432.CCR-10-2275. Epub 2010 Oct 29
   PubMed Web of Science ®Google Scholar
• Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, Dimitrov DS. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Therap 2009; 8:1113-1118; PMID:19417159; http://dx.doi.org/10.1158/1535-7163.MCT-08-0945
   PubMed Web of Science ®Google Scholar
• Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high affinity human monoclonal antibody to mesothelin. Int J Cancer 2011; 128:2020-2030; PMID:20635390; http://dx.doi.org/10.1002/ijc.25557
   PubMed Web of Science ®Google Scholar
• Yamasaki H, Ikeda S, Okajima M, Miura Y, Asahara T, Kohno N, Shimamoto F. Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors. Int J Oncol 2004; 24:107-113; PMID:14654947; http://dx.doi.org/10.3892/ijo.24.1.107
   PubMed Web of Science ®Google Scholar
• Qu CF, Li Y, Song YJ, Rizvi SM, Raja C, Zhang D, Samra J, Smith R, Perkins AC, Apostolidis C, et al. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. British J Cancer 2004; 91:2086-2093; PMID:15599383; http://dx.doi.org/10.1038/sj.bjc.6602232
   PubMed Web of Science ®Google Scholar
• Levi E, Klimstra DS, Andea A, Basturk O, Adsay NV. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004; 57:456-462; PMID:15113850; http://dx.doi.org/10.1136/jcp.2003.013292
   PubMed Web of Science ®Google Scholar
• Tsutsumida H, Swanson BJ, Singh PK, Caffrey TC, Kitajima S, Goto M, Yonezawa S, Hollingsworth MA. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res 2006; 12:2976-2987; PMID:16707592; http://dx.doi.org/10.1158/1078-0432.CCR-05-1197
   PubMed Web of Science ®Google Scholar
• Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer 2004; 109:618-626; PMID:14991585; http://dx.doi.org/10.1002/ijc.20004
   PubMed Web of Science ®Google Scholar
• Danielczyk A, Stahn R, Faulstich D, Löffler A, Märten A, Karsten U, Goletz S. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol, Immunother 2006; 55: 1337-1347; PMID:16485130; http://dx.doi.org/10.1007/s00262-006-0135-9
   PubMed Web of Science ®Google Scholar
• Fan XN, Karsten U, Goletz S, Cao Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol, Res Practice 2010; 206:585-589; PMID:20400237; http://dx.doi.org/10.1016/j.prp.2010.03.006
   PubMed Web of Science ®Google Scholar
• Pratesi G, Petrangolini G, Tortoreto M, Addis A, Zunino F, Calcaterra C, Merlo A, Tagliabue E, Menard S, Balsari A. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 2008; 31:537-544; PMID:18528301; http://dx.doi.org/10.1097/CJI.0b013e31817c37ff
   PubMed Web of Science ®Google Scholar
• Saeki H, Yanoma S, Takemiya S, Sugimasa Y, Akaike M, Yukawa N, Rino Y, Imada T. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2- overexpressing pancreatic cancer. Oncol Rep 2007; 18:433-439; PMID:17611667; http://dx.doi.org/10.3892/or.18.2.433
   PubMed Web of Science ®Google Scholar
• Larbouret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pèlegrin A, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas,” Clin Cancer Res 2007; vol. 13, no. 11, pp. 3356-3362; PMID:17545543; http://dx.doi.org/10.1158/1078-0432.CCR-06-2302
   PubMed Web of Science ®Google Scholar
• Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin A, Azria D. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol 2010; 21:98-103; PMID:19889608; http://dx.doi.org/10.1093/annonc/mdp496
   PubMed Web of Science ®Google Scholar
• Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol, Immunother 2005; 54: 315-327; PMID:15592930; http://dx.doi.org/10.1007/s00262-004-0597-6
   PubMed Web of Science ®Google Scholar
• A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma (NCT00041639). Available at http:clinicaltrials.gov
   Google Scholar
• Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Klöppel G, Hall PA, Gullick WJ. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992; 166:166:7-12; PMID:1538276
   PubMed Web of Science ®Google Scholar
• Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13:565-569; PMID:8317885
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60:2926-2935; PMID:10850439
   PubMed Web of Science ®Google Scholar
• Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Therap 2002; 1:777-783; PMID:12492110
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Int J Oncol 2005; 23:2445-2459; PMID:15753456; http://dx.doi.org/10.1200/JCO.2005.11.890
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, et al. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group- Directed Intergroup Trial S0205. J Clin Oncol 2010; 28: 3605-3610; PMID:20606093; http://dx.doi.org/10.1200/JCO.2009.25.7550
   PubMed Web of Science ®Google Scholar
• Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, et al. Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: A prospective phase II trial [PARC-Study ISRCTN56652283]. J Clin Oncol 2007; 25:4573; PMID:16219105; http://dx.doi.org/10.1186/1471-2407-5-131
   PubMed Web of Science ®Google Scholar
• Bangard C, Gossmann A, Papyan A, Tawadros S, Hellmich M, Bruns CJ. Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Int J Cancer 2005; 114:131-138; PMID:15523683; http://dx.doi.org/10.1002/ijc.20696
   PubMed Web of Science ®Google Scholar
• Graeven U, Kremer B, Südhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmiegel W. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British J Cancer 2006; 94:1293-1299; PMID:16622465; http://dx.doi.org/10.1038/sj.bjc.6603083
   PubMed Web of Science ®Google Scholar
• Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003; 2:8; PMID:12556241; http://dx.doi.org/10.1186/1476-4598-2-8
   PubMedGoogle Scholar
• Karayiannakis AJ, Bolanaki H, Syrigos KN, Asimakopoulos B, Polychronidis A, Anagnostoulis S, Simopoulos C. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003; 194:119-124; PMID:12706865; http://dx.doi.org/10.1016/S0304-3835(03)00047-8
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23:8033-8040; PMID:16258101; http://dx.doi.org/10.1200/JCO.2005.01.9661
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2007; 28:3617-3622; PMID:20606091; http://dx.doi.org/10.1200/JCO.2010.28.1386
   PubMed Web of Science ®Google Scholar
• Bruckner HW, Hrehorovich VR, Sawhney HS. Bevacizumab as treatment for chemotherapyresistant pancreatic cancer. Anticancer Res 2005; 25:3637-3639; PMID:16101193
   PubMed Web of Science ®Google Scholar
• Hensler T, Hecker H, Heeg K, Heidecke CD, Bartels H, Barthlen W, Wagner H, Siewert JR, Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997; 65:2283-91; PMID:9169765
   PubMed Web of Science ®Google Scholar
• Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann Surg Oncol 2003; 10:972-92; PMID:14527919
   PubMed Web of Science ®Google Scholar
• Weighardt H, Heidecke CD, Emmanuilidis K, Maier S, Bartels H, Siewert JR, Holzmann B. Sepsis after major visceral surgery is associated with sustained and interferon-γ resistant defects of monocyte cytokine production. Surgery. 2000; 127:309-15; PMID:10715987
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Homma S, Namiki Y, Komita H, Takahara A, Nagasaki E, Ito M, Sagawa Y, Mitsunaga M, et al. Dendritic/pancreatic carcinoma fusions for clinical use: comparative functional analysis of healthy- versus patient-derived fusions. Clin Immunol 2010; 135:384-400; PMID:20226739
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 2005; 11:7891-900; PMID:16278414
   PubMed Web of Science ®Google Scholar
• Saito H, Dubsky P, Dantin C, Finn OJ, Banchereau J, Palucka AK. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res 2006; 8:R65; PMID:17129372
   PubMedGoogle Scholar
• Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19:145-56; PMID:11134207
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19:145-56; PMID:11134207
   PubMed Web of Science ®Google Scholar
• Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008; 14:1455-63; PMID:18316569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43; PMID:8097319
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011; 253:328-35; PMID:21217520; http://dx.doi.org/10.1097/SLA.0b013e3181fd271c
   PubMed Web of Science ®Google Scholar
• Dung TLe, Andrea Wang-Gillam, Vincent J Picozzi, Tim F Greten, Todd S Crocenzi, Gregory M Springett, Michael Morse, Herbert Zeh, Deirdre Jill Cohen, Robert Lance Fine, et al. Brockstedt, Elizabeth M. Jaffee; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Washington University School of Medicine in St. Louis, St. Louis, MO; Virginia Mason Medical Center, Seattle, WA; National Cancer Institute, Bethesda, MD; Providence Cancer Center, Portland, OR; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Duke University Medical Center, Durham, NC; University of Pittsburgh Medical Center, Pittsburgh, PA; New York University Cancer Institute, New York, NY; Columbia University, New York, NY; Aduro BioTech, Inc., Berkeley, CA Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. J Clin Oncol 31, 2013 (suppl; abstr 4040^).
   Google Scholar
• ClinicalTrials.gov identifier:NCT00727441.
   Google Scholar
• Dung T, Wang-Gillam A, Picozzi Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. J Clin Oncol 2014; 32(suppl 3):Abstract 177.
   Google Scholar
• Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg 2013; 17:94-100; PMID:23229886; http://dx.doi.org/10.1007/s11605-012-2064-6
   PubMed Web of Science ®Google Scholar
• Adsay NV, Basturk O, Cheng JD, Andea AA. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol 2005; 15:254-64; PMID:16183479.; http://dx.doi.org/10.1016/j.semradonc.2005.04.001
   PubMed Web of Science ®Google Scholar
• Gaudernack G. Prospects for vaccine therapy for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20:299-314; PMID:16549329
   PubMed Web of Science ®Google Scholar
• Capello M, Ferri-Borgogno S, Cappello P, Novelli F. α-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 2011; 278:1064-74; PMID:21261815; http://dx.doi.org/10.1111/j.1742-4658.2011.08025.x
   PubMed Web of Science ®Google Scholar
• Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6:404-14; PMID:17473845
   PubMed Web of Science ®Google Scholar
• Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007; 6:591-603; PMID:17669012
   PubMed Web of Science ®Google Scholar
• Kanodia S, Kast WM. Peptide-based vaccines for cancer: realizing their potential. Expert Review of Vaccines 2008; 7:1533-45; PMID:19053209
   PubMed Web of Science ®Google Scholar
• Voskens CJ, Strome SE, Sewell DA. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Current Molecular Medicine 2009; 9:683-93; PMID:19689295
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009; 16:4779-96; PMID:19929787
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl T 3rd, Stokke KT, Sølheim BG, Egge TS, Søreide O, Thorsby E, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996; 65:450-3; PMID:8621226
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Søreide O, Thorsby E, Gaudernack G. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995; 346:1399-400; PMID:7475823
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92:441-50; PMID:11291084
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Brennan MF, Capanu M, Gansukh B, Jacobs G, Levin A, Neville D, Kelsen DP, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011; 34:321-5; PMID:20686403; http://dx.doi.org/10.1097/COC.0b013e3181e84b1f
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006; 95:1474-82; PMID:17060934
   PubMed Web of Science ®Google Scholar
• Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol 2013; 5:81-9; PMID:23323149; http://dx.doi.org/10.1177/1758834012462463
   PubMed Web of Science ®Google Scholar
• Monstein HJ, Ohlsson B, Axelson J. Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines. Scand J Gastroenterol 2001; 36:738-43; PMID:11444473
   PubMed Web of Science ®Google Scholar
• Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, Whitehead A, Takhar A, Rowlands BJ, Beckingham IJ. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 2012; 41:374-9; PMID:22228104; http://dx.doi.org/10.1097/MPA.0b013e31822ade7e
   PubMed Web of Science ®Google Scholar
• Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92(2):271-8; PMID:11466679
   PubMed Web of Science ®Google Scholar
• Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55:1294-8; PMID:16315030
   PubMed Web of Science ®Google Scholar
• Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, Imamura M, Torigoe T, Takahashi A, Hirohashi Y, et al. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 2013; 104:124-9; PMID:23078230; http://dx.doi.org/10.1111/cas.12046
   PubMed Web of Science ®Google Scholar
• Fałkowska-Podstawka M, Wernicki A. Heat shock proteins in health and disease. Pol J Vet Sci 2003; 6:61-70; PMID:12675471
   PubMedGoogle Scholar
• Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK, Brennan MF. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007; 52:1964-72; PMID:17420942
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med 2007; 5:60; PMID:18039393
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 2007; 27:451-62; PMID:18197807
   PubMed Web of Science ®Google Scholar
• Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer 2009; 125:639-48; PMID:19425054; http://dx.doi.org/10.1002/ijc.24355
   PubMed Web of Science ®Google Scholar
• Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, Migliorini P, Salacone P, Novarino A, Giacobino A, Ciuffreda L, et al. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res 2011; 10:105-12; PMID:20455595; http://dx.doi.org/10.1021/pr100213b
   PubMed Web of Science ®Google Scholar
• Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012; 142:1079-92; PMID:22406637; http://dx.doi.org/10.1053/j.gastro.2012.03.002
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-83; PMID:15894267
   PubMed Web of Science ®Google Scholar
• Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, Perconti G, Feo S, Giovarelli M, Novelli F. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology 2013; 144:1098-106; PMID:23333712; http://dx.doi.org/10.1053/j.gastro.2013.01.020
   PubMed Web of Science ®Google Scholar
• Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008; 6:955-64; PMID:19129927
   PubMedGoogle Scholar
• Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012; 41:195-205; PMID:21792083; http://dx.doi.org/10.1097/MPA.0b013e31822398c6
   PubMed Web of Science ®Google Scholar
• Goggins M, Kern SE, Offerhaus JA, Hruban RH. Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol 1999; 4:4-8; PMID:10436774
   PubMed Web of Science ®Google Scholar
• Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008; 68:889-92; PMID:18245491; http://dx.doi.org/10.1158/0008-5472.CAN-07-3095
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 2013; 144:1230-40; PMID:23622132; http://dx.doi.org/10.1053/j.gastro.2012.12.042
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; http://dx.doi.org/10.1097/CJI.0b013e3181eec14c
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2
   PubMed Web of Science ®Google Scholar
• Bazhin AV, Shevchenko I, Umansky V, Werner J, Karakhanova S. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunol Immunother 2014; 63:59-65; PMID:24129765; http://dx.doi.org/10.1007/s00262-013-1485-8
   PubMed Web of Science ®Google Scholar
• Niccolai E, Prisco D, D’Elios MM, Amedei A. What is recent in pancreatic cancer immunotherapy? Biomed Res Int 2013; 2013:492372; PMID:23509731; http://dx.doi.org/10.1155/2013/492372
   PubMed Web of Science ®Google Scholar